Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Precision STING delivery could help convert immune-desert tumors into inflamed tumors

A new review highlights the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway as a central switch that can convert immunologically "cold" tumors into "hot," inflamed tumors and improve immunotherapy responses. The authors synthesize how acute activation of this innate immune sensor promotes antigen presentation, T-cell priming, and type I interferon (IFN-I) signaling, while chronic or mistimed activation can drive immunosuppression, metastasis, and treatment resistance. The review maps next-generation STING-targeted agonists and delivery platforms--including antibody-drug conjugates (ADCs), immune-stimulating antibody conjugates (ISACs), nanoparticles, bacterial vectors, and exosomes--to distinct tumor microenvironment (TME) phenotypes. It proposes a strategic framework for rational combination therapies and biomarker-driven patient selection.

October 16, 2026


October 16 2026

October 15 2026

October 14 2026

October 13 2026

October 12 2026

October 11 2026

October 10 2026

October 9 2026

October 8 2026

October 7 2026

October 6 2026

October 5 2026

October 2 2026